Benzinga | Jun 23, 2021 07:47AM EDT

Baird Maintains Neutral on Intellia Therapeutics, Raises Price Target to $85

Baird analyst Madhu Kumar maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $60 to $85.